SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " GLP " 375 found 🔀 AI-powered Shuffle
Why quitting Ozempic and GLP-1s can be bad for your heart health
People who quit taking popular GLP-1 drugs such as Ozempic might their jeopardize heart health, according to a new study.
Heart benefits fade after stopping GLP-1 medications
One major benefit of taking injected GLP-1 medications is a sizeable reduction in risk for heart attacks, strokes and other heart problems.
An NIH whistleblower warning
The doctors behind the telehealth GLP-1 boom, a men's health office moment, and other health news
Exclusive: Sword Health launches GLP-1 program as it eyes more deals
The company is weighing more M&A and an IPO as early as next year.
Stock Market Today, March 9: Hims & Hers Health Soars on Novo Nordisk Weight-Loss Drug Deal
On March 9, 2026, a new Novo Nordisk pact reshaped this telehealth player’s GLP-1 strategy, margins, and legal risk profile.
Weight Loss Drugs Like Ozempic and Wegovy Show Surprising Heart Health Benefits
A new study suggests that widely used GLP-1 weight-loss drugs may do more than improve metabolic health: they could also protect the heart after a heart attack. Doctors can often reopen the blocked artery that triggers a heart attack, but that is not always the end of the crisis inside the heart
Giving GLP-1 users bite-sized nudges toward healthy habits
Stanford Medicine study shows digital lifestyle nudges may catalyze a critical first step towards behavior change for those taking GLP-1 medications.
Hims & Hers Announces Strategic Shift for US Weight Loss Business
Starting with a new collaboration with Novo Nordisk, the company announced plans to align its US and global strategies with a focus on an increasing variety of FDA-approved GLP-1s Hims Hers Health, Inc. (NYSE: HIMS) today announced a collaboration with Novo Nordisk as part of a new strategy for weight loss care treatments involving GLP-1s, evolving its US offering to match the company’s approach globally. In the US, the company now plans to provide GLP-1 customers with access to a broad assortment of FDA-approved medications and offer compounded semaglutide through the platform on a limited scale. By aligning its domestic and international models in weight loss, Hims Hers will become the largest global consumer health platform for access to more affordable, approved medications. The US weight loss landscape has transformed dramatically since Hims Hers entered the market in 2023. Progress in the industry has made a broader range of FDA-approved GLP-1 treatments
GLP-1 Patients Report New Side Effect—and It’s Worse Than ‘Ozempic Face’
It won’t ruin your face or butt, but it might ruin your life—at least for a little while.
GLP-1 Drugs May Raise the Risk of Osteoporosis and Gout, Study Suggests
New research suggests that prolonged GLP-1 use may increase the risk of certain bone and joint conditions.
GLP-1 Weight-Loss Drugs Prove Effective Across Diverse Patient Groups
By Deanna Neff HealthDay ReporterFRIDAY, March 6, 2026 (HealthDay News) — As the popularity of medications like Ozempic and Trulicity for losing weight continues to soar, folks may wonder: "Will they work for me?" Researchers at Johns Hopkins Bloomberg School of Public Health sought to shed light on ...
Most Patients Keep Weight Off With Fewer GLP-1 Shots, Study Finds
In a recent review, a small group of patients received the injections less frequently but still maintained weight loss and health benefits.
‘Enough’ with blame and shame: The science behind obesity and GLP-1s
In a new book, Yale endocrinologist Ania Jastreboff teams up with Oprah Winfrey to transform how we think about health, weight, and obesity.
Hims expansion may not come in time for risky GLP-1 business
Telehealth company Hims & Hers Health , known for its weight-loss drug business, is promising it can diversify away from its reliance on compounded GLP-1 sales in the U.S., but that may not happen soon enough for investors who are growing impatient.
GLP-1s may increase risk of osteoporosis and gout, new research finds
A large analysis suggests the popular weight loss drugs may carry an increased risk to bone health.
How A $200 Million Pea Protein Business Is Fueling The Ozempic Generation
Since the 1980s, the Lorenzen family has grown its protein powder business, Puris, into an AgTech power player. Now the preferred supplier for food brands seeking craveable recipes for GLP-1 users—it’s helping America become ‘protein independent
Eli Lilly's orforglipron beats Novo Nordisk's GLP-1 pill in tests
Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be available this spring.
In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding
In earnings call, Hims & Hers CEO Andrew Dudum addressed the increased scrutiny on compounded GLP-1s and its impact on the business’s bottom line.
Guardians News and Notes: Adding a Win and a Hoskins
News and Notes for Monday, February 23rd, 2026
Sarah Ferguson checked into mental health clinic after Epstein emails surfaced
Ex-wife of Andrew Mountbatten-Windsor stayed at £13,000-a-day wellness centre in Zurich, say reports
Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China
Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and sweeping changes to vaccine policy.
General Mills Wants to Win Health-Conscious Shoppers; Cut in Outlook Slams Stock
General Mills is getting aboard the GLP-1 train as the company navigates shaky consumer sentiment. Chief Executive Jeff Harmening told investors Tuesday that the weight-loss drugs will have a lasting influence on the business of food, nudging some consumers toward smaller portions, and more nutrien
Employers find new option for workers' GLP-1 demand
Workers want access to GLP-1s, and employers want to avoid the cost of obesity-related illness.
Recent Louisa business closures highlight ongoing work to support local economy
As owners face challenges, the town and county say they’re working together to support businesses.
Mass. fun factory offers Boston-themed laser tag, the biggest pretzel you’ll ever see
Apex in Marlborough is way more than just another entertainment center. I mean, have you seen this pretzel?
Gen Z has perfected the glorious art of boredom as entertainment
Streaming isn’t depressing at all. It might be the most hopeful thing I’ve seen in years
A look around Apex Entertainment in Marlborough.
A look around Apex Entertainment in Marlborough.
GLP-1 Envy Was Just the Beginning
A Super Bowl ad by Hims & Hers sells the idea that everyone should want to be billionaire-healthy.
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
Eli Lilly is the leader in the GLP-1 space, but here's another GLP-1 stock and a medical device maker to consider.
The Weight-Loss Price Wars Are Breaking Big Pharma’s Business Model
Prices for GLP-1s are falling fast, forcing companies to adapt.
Health Agency Refers Knockoff GLP-1 Provider Hims & Hers to Justice Department
The FDA said it would take “decisive steps” to restrict nonapproved drugs that use GLP-1 active pharmaceutical ingredients.
Seals Are Seemingly Vanishing Off the Dutch Coast. These Scientists Are Trying to Get to the Bottom of the Mysterious Disappearances
Recent counts of the Wadden Sea’s adult harbor seal population have revealed a surprising trend of decline, prompting a consortium of researchers to investigate whether the animals are dying off, relocating or experiencing something else altogether
What the shape of your bottom reveals about your health
Round, pear-shaped or saggy? Your gluteus maximus muscles can be an important indicator of overall health
Hometown Health: VDH reporting first pediatric flu-related death, GLP 1’s reducing cancer risk, and taking away the excuse of cold weather for not exercising
The department says the child was preschool aged living in the eastern region of Virginia.
The Scary Health Risk That Can Sneak Up on GLP-1 Users
Next gen weight-loss medications are powerful — but eating too little can put some patients at serious nutritional risk.
Matt Damon says Netflix wants plot repeated 3 or 4 times in movies for viewers watching while on their phones
While promoting his new Netflix movie, Matt Damon said the streamer 'standard way to make an action movie' in light of people watching while on their phones.
What science says about how weight-loss drugs affect cancer risk
Evidence is mounting that GLP-1 drugs may play a role in reducing cancer risk and deaths from certain cancers.
The ‘bombshell’ science that casts doubt on claims about microplastics
Like tobacco and asbestos before, these particles have sparked widespread fear. But now experts say the risks may be overstated
Can the American Oboe Sing Again?
Building the instrument is hard enough. Turning a profit is a killer. But Jim Phelan is bent on reviving one of the great names in classical music.
Why Hims & Hers Health (HIMS) Is Down 6.8% After Amazon Pharmacy Adds Wegovy Weight-Loss Pill
In recent days, Amazon Pharmacy announced it would begin offering Novo Nordisk’s Wegovy once-daily weight-loss pill through both insurance and cash-pay channels, including future availability via its pharmacy kiosks. This move directly targets the fast-growing weight management segment where Hims & Hers Health participates, raising fresh questions about how differentiated and resilient its broader telehealth platform and recurring-care model really are beyond GLP-1 offerings. We’ll now...
Nutrition Strategies to Improve Health With Protein, Fiber, Carbs
Following the release of a new food pyramid and dietary guidelines for Americans, nutrition expert and author of "The Whole Body Reset," Heidi Skolnick joins TODAY with what the recommendations mean for you, how to pace protein intake, how to get more fiber in your diet through foods, what people on GLP-1s should keep in mind about the new guidelines and more.
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference
One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 12-week data from Phase 1 trial of MBX 4291, a dual GLP-1/GIP co-agonist prodrug with potential for once-monthly dosing and improved tolerability for obesity, anticipated in Q4 2026 Nomination of two additional obesity candidates expected in 2026: an amycretin prodrug and a GLP-1/GIP/GCGR triple agonist,
Noom launches a GLP-1-based, long-term, preventive health care program
Noom is expanding the ways it can help people develop long-term health and wellness with the new Proactive Health GLP-1 Program.
The Weight-Loss Drug Revolution—From Shots to Pills and the Science behind It All
Behind the hype of GLP-1 medications lies complex science, serious side effects and a pharmaceutical arms race.
Stopping obesity drugs means people regain weight and lose heart health benefits
Why the weight, and heart risks, return after stopping GLP-1 drugs.
Trump, RFK dramatically overhaul child vaccine schedule
The move is a public health gamble that assumes children's health won't be endangered by cutting the shots they get.
Top Health Trends of 2026: GLP-1 Expansion, AI Wearables, More
Which health trends will be making the biggest waves in 2026? Gretel Schueller, managing editor of health at U.S. News and World Report, joins TODAY to share an exclusive look at their list of the top emerging health trends, including an expansion of GLP-1s for more health conditions, the integration of AI into wearable technology and more.
The science of losing weight : Life Kit: Health
When it comes to weight loss, there are many misconceptions about what works. So if you want to lose weight this year, here's what the science says about the potential health benefits, GLP-1 drugs, exercise and more.Sign up for Life Kit's Guide to Building Strength here: npr.org/strongerFollow us on Instagram: @nprlifekitSign up for our newsletter here.Have an episode idea or feedback you want to share? Email us at lifekit@npr.orgSupport the show and listen to it sponsor-free by signing up for Life Kit+ at plus.npr.org/lifekit
The science of losing weight : Life Kit: Health
When it comes to weight loss, there are many misconceptions about what works. So if you want to lose weight this year, here's what the science says about the potential health benefits, GLP-1 drugs, exercise and more.Sign up for Life Kit's Guide to Building Strength here: npr.org/strongerFollow us on Instagram: @nprlifekitSign up for our newsletter here.Have an episode idea or feedback you want to share? Email us at lifekit@npr.orgSupport the show and listen to it sponsor-free by signing up for Life Kit+ at plus.npr.org/lifekit
The science of losing weight : Life Kit
When it comes to weight loss, there are many misconceptions about what works. So if you want to lose weight this year, here's what the science says about the potential health benefits, GLP-1 drugs, exercise and more.Sign up for Life Kit's Guide to Building Strength here: npr.org/strongerFollow us on Instagram: @nprlifekitSign up for our newsletter here.Have an episode idea or feedback you want to share? Email us at lifekit@npr.orgSupport the show and listen to it sponsor-free by signing up for Life Kit+ at plus.npr.org/lifekit
Next stop: Minnesota
The Packers departed Green Bay's Austin Straubel International Airport on Saturday, Jan. 3, 2026, heading to Minnesota ahead of their Week 18 matchup against the Vikings.
2026 Health Care Predictions: AI, GLP-1s, MAHA, DEI: Sachin H. Jain, MD, MBA
Sachin H. Jain, MD, MBA, discusses 2026 health care predictions, including AI adoption, GLP-1 demand, MAHA growth, DEI’s return, and policy shifts.
In 2026, Kennedy’s MAHA vision gets put to the test. Here are 3 issues to watch
In 2026, Robert F. Kennedy Jr.'s health policy changes will start playing out on GLP-1s, dietary guidelines, and rural health initiatives.
US health agency to negotiate prices for GLP-1 weight-loss drugs
The U.S. Centers for Medicare and Medicaid Services said on Tuesday it will negotiate drug prices with manufacturers of GLP-1 medications, in an attempt to expand access to the weight-loss treatments.
With FDA approval of Wegovy pill, new era of oral GLP-1 weight loss drugs begins
With FDA approval of Wegovy pill, new era of oral GLP-1 weight loss drugs begins
3 markers of health could help with weight-loss strategies, obesity expert reveals
Obesity medicine specialist Dr. Rocio Salas-Whalen, M.D., author of the new book "Weightless," shared that the best way to determine the suitability of a GLP-1 is through body composition testing.
Why dogs love you so much, according to science
Thousands of years of history have secured their status as man’s best friend – and there are ways to strengthen the bond even further
Opinion | GLP 1s: 14 Users Discuss
The participants discuss their experiences with taking GLP 1s for weight loss and diabetes.
Riddle of nuclear science professor shot dead at home
Tributes pour in as murder hunt launched after three gunshots heard
These people lost their sense of taste. Are GLP-1s to blame?
GLP-1s mute sugar in our bodies. That's impacting our taste buds.
Growing GLP‑1 drug costs squeeze Minnesota employers and health plans
The Metropolitan Airports Commission recently moved to cut coverage for weight loss medications, citing cost concerns.
Nine science-backed ways to prevent overeating this Christmas
Flavour perception and food presentation can affect our brain and make us feel fuller earlier, so we eat fewer calories
These new 2026 health care laws are taking effect in Pa., N.J. and Del.
Bills on diagnostic breast cancer testing, GLP-1 medications, lead paint and breastfeeding were signed into law.
GLP-1s may weaken the pelvic floor, impacting women's health –– and their sex lives
GLP-1 side effects like constipation and muscle mass loss can lead to uncomfortable pelvic floor symptoms like bladder leakage and painful sex.
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat (3.5 lbs; p=0.07), and a 3.2% increase in lean mass (4.0 lbs; p=0.01), with no statistically significant changes in the placebo group Sustained and robust suppression of serum Activin E supports expectations for continued improvements in body composition, further fat loss, and p
Driven by GLP-1s, prescription drug spending explodes at major health insurers
Some insurers have spent more on drugs in nine months this year than they did in all of 2024. Cost of weight loss drugs a major factor, STAT analysis finds.
It’s official, politics has ruined Eurovision
A toxic anti-Israel boycott has created the biggest crisis in the song contest’s history – it’s hard to see how it can move forward
Here’s What the World Health Organization Had to Say About GLP-1s in its First-Ever Guideline on the Drugs
The health agency supports the long-term use of the medications in combination with a healthy diet and exercise, and calls for equitable access to the drugs
World Health Organization issues guidelines for GLP-1 weight loss medication use
Fox News senior medical analyst Dr. Marc Siegel discusses the World Health Organization announcing its first guidelines on weight loss drugs, his book ‘The Miracles Among Us’ and its Fox Nation special on ‘America’s Newsroom.’
Google Patches 107 Android Flaws, Including Two Framework Bugs Exploited in the Wild
Google Patches 107 Android Flaws, Including Two Framework Bugs Exploited in the Wild | Read more hacking news on The Hacker News cybersecurity news website and learn how to protect against cyberattacks and software vulnerabilities.
World Health Organization recommends GLP-1 drugs for obesity
The World Health Organization is now recommending GLP-1 drugs for adults trying to manage obesity. Dr. Natalie Azar explains how this historical shift changes the approach for patients.
WHO issues guidance on GLP-1 drugs for obesity, calls them a "scientific breakthrough" and "new chapter"
WHO issues global guideline on the use of GLP-1 medicines in treating obesity
To address the growing global health challenge of obesity, which affects more than 1 billion people, WHO has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease.
World Health Organization recommends GLP-1s for obesity. There's a catch.
The WHO issued guideline on the use of GLP-1 therapies for obesity, conditionally recommending them as part of long-term treatment.
WHO recommends GLP-1 drugs for obesity
The weight loss medications can be part of a long-term treatment strategy for adults, according to new World Health Organization guidelines.